Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
EDSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.55 - $5.00
Previous CloseN/A
Volume1.31K
Average Volume (3M)30.54K
Market Cap
$15.73M
Enterprise Value$11.12M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Dec 12, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding7,037,648
10 Day Avg. Volume17,704
30 Day Avg. Volume30,541
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-216.22
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$7.00Price Target Upside208.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentHealth Canada has approved Edesa Biotech to conduct a Phase 2 trial of EB06 in moderate to severe nonsegmental vitiligo patients.
Financial PositionEdesa’s balance sheet is robustly positioned for the manufacturing of clinical-grade supplies of EB06, supported by $15M in gross proceeds from a recent private placement.
Market PotentialThe prioritization of EB06, a monoclonal antibody candidate for the treatment of vitiligo, represents a significant market opportunity due to the large number of affected individuals in the U.S.
Bears Say
Market CompetitionEB06 has potential advantages in safety and dosing, which could drive significant market adoption despite the presence of several competitors in the vitiligo market.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $1.55 and its highest was $5.00 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is $15.73M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is Dec 12, 2025 which is in 114 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Aug 08, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.013.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Undervalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.28.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 7,037,648 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -0.472%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
Company Description
Edesa Biotech Inc
Edesa Biotech (EDSA) is a clinical-stage biopharmaceutical company that focuses on the development of innovative treatments for inflammatory and immune-related diseases. Operating primarily in the biotechnology sector, the company aims to address unmet medical needs by advancing its pipeline of novel drug candidates. Edesa Biotech's core products include monoclonal antibodies and other biologics designed to modulate the immune response and provide therapeutic solutions for conditions such as allergic and inflammatory diseases.
EDSA Stock 12 Month Forecast
Average Price Target
$7.00
▲(208.37% Upside)
Technical Analysis
Palatin Technologies
―
Accelerate Diagnostics
―
Lipocine
―
Nephros
―
Inspira Technologies Oxy BHN
―
Ownership Overview
24.61% Insiders
0.55% Mutual Funds
28.42% Other Institutional Investors
46.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---